GSK India managing director Sridhar Venkatesh outlines how the company navigated pandemic-related turbulence and “stuck its neck out” to ensure uninterrupted supplies of key drugs. The executive also discusses launch prospects for products including Xevudy in India and an intent to “refresh” the company’s vaccines portfolio.
Sridhar Venkatesh moved from Singapore to take over the top job as managing director at GlaxoSmithKline Pharmaceuticals Ltd. in India bang in the middle of the pandemic in 2020.
Flying into India was kind of a “surreal” experience, the executive recalls, referring to the protective attire he donned to make it through safely.